Related Experiment Video
Updated: May 24, 2025

Osteoclast Derivation from Mouse Bone Marrow
Published on: November 6, 2014
Medication-related osteonecrosis of the jaw in an older patient with multiple myeloma
Larissa Couto de Freitas1, Vanessa Silvestre de Aquino Silva1, Marta Miyazawa1
1School of Dentistry, Federal University of Alfenas, Alfenas, Minas Gerais, Brazil.
Objective:
This article reports a case of medication-related osteonecrosis of the jaw (MRONJ) associated with multiple myeloma (MM).
Background:
Bisphosphonates (BPs) are constantly used as part of the treatment for MM. The main adverse effects of bisphosphonates are renal insufficiency and medication-related osteonecrosis of the jaw (MRONJ).
Materials And Methods:
A 67-year-old female with a previous diagnosis of MM and undergoing current receiving intravenous injections of pamidronate underwent a tooth extraction and subsequently developed MRONJ.
Results:
MRONJ was managed with clindamycin, surgical removal of bony sequestrum and curettage. At 3 years of follow-up, the patient was asymptomatic with no clinical changes and panoramic radiography without evidence of recurrence.
Conclusion:
Management of patients under antiresorptive drugs who require invasive dental procedures is challenging. Therefore, interprofessional collaboration, especially between the general practitioner and oncologist and/or haematologist, is essential to reach the best clinical approach and reduce the risk of MRONJ.
Insights
This case study highlights medication-related osteonecrosis of the jaw (MRONJ) in a multiple myeloma patient treated with bisphosphonates. Successful management involved antibiotics and surgery, emphasizing collaborative care to prevent MRONJ.
Area of Science:
- Oncology
- Oral Surgery
- Pharmacology
Background:
- Multiple myeloma (MM) treatment frequently involves bisphosphonates (BPs).
- Bisphosphonates carry risks including renal insufficiency and medication-related osteonecrosis of the jaw (MRONJ).
Observation:
- A 67-year-old female with MM receiving intravenous pamidronate developed MRONJ post-tooth extraction.
- The patient presented with symptoms of MRONJ following dental surgery.
Findings:
- MRONJ was successfully treated with clindamycin, surgical debridement, and sequestrum removal.
- After three years, the patient remained asymptomatic with no radiographic signs of MRONJ recurrence.
Implications:
- Managing patients on antiresorptive therapy undergoing dental procedures is complex.
- Interprofessional collaboration between general practitioners, oncologists, and hematologists is crucial for optimal MRONJ risk reduction and patient care.
More Related Videos
11:47A Novel in vivo Gene Transfer Technique and in vitro Cell Based Assays for the Study of Bone Loss in Musculoskeletal Disorders
Published on: June 8, 2014
09:09Treatment with Vancomycin Loaded Calcium Sulphate and Autogenous Bone in an Improved Rabbit Model of Bone Infection
Published on: March 14, 2019
Related Concept Videos
Bone Disorders
Bone deposition is also affected by the levels of sex hormones like estrogen and testosterone that promote osteoblast activity and bone matrix synthesis. When the level of these hormones decreases due to aging, it causes a reduction in bone deposition. As a result, bone resorption by osteoclasts...
Osteoclasts in Bone Remodeling
Peptic Ulcer Disease IV: Management
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Bone Remodeling